Literature DB >> 2874132

Factor V is a substrate for the transamidase factor XIIIa.

R T Francis, J McDonagh, K G Mann.   

Abstract

Coagulation Factor V (Mr = 330,000), upon cleavage by thrombin, produces Factor Va, which is composed of two subunits with Mr values of 94,000 and 74,000, along with two activation fragments possessing no known function. Studies were undertaken to assess the ability of the transamidase Factor XIIIa to covalently incorporate the lysine analogs [3H]putrescine and dansylcadaverine into the thrombin-cleaved (activated) and unactivated forms of human and bovine Factor V. The incorporation of either probe into thrombin-activated Factor V proceeded at an initial rate approximately twice that for unactivated Factor V. The extent of the incorporation of [3H]putrescine or dansylcadaverine into activated or unactivated human Factor V was identical; 4 mol of either probe per mol of Factor V. In the case of bovine Factor V, however, while 4 mol of probe were bound per mol of the unactivated pro-cofactor, 5 mol of either lysine analog were covalently linked to 1 mol of thrombin-cleaved Factor V. Polyacrylamide gel fluorography, immunoaffinity chromatography, and immunoprecipitation identified the largest activation fragment of human Factor V (Mr = 150,000) and bovine Factor V (Mr = 120,000) to contain the sites of incorporation of the covalently bound probes. High molecular weight, apparently covalent polymers of Factor V were produced by the action of Factor XIIIa on activated and unactivated human or bovine Factor V. The absence of either probe in the reaction mixtures did not appear to allow an enhancement of protein polymerization.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874132

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase.

Authors:  Ammon M Fager; Jeremy P Wood; Beth A Bouchard; Ping Feng; Paula B Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Post-translational modification of apolipoprotein B by transglutaminases.

Authors:  E Cocuzzi; M Piacentini; S Beninati; S I Chung
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

4.  Complete cDNA and derived amino acid sequence of human factor V.

Authors:  R J Jenny; D D Pittman; J J Toole; R W Kriz; R A Aldape; R M Hewick; R J Kaufman; K G Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

6.  Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C.

Authors:  R M Mesters; M J Heeb; J H Griffin
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

7.  The role of β-barrels 1 and 2 in the enzymatic activity of factor XIII A-subunit.

Authors:  E L Hethershaw; P J Adamson; K A Smith; W N Goldsberry; R J Pease; S E Radford; P J Grant; R A S Ariëns; M C Maurer; H Philippou
Journal:  J Thromb Haemost       Date:  2018-05-27       Impact factor: 5.824

Review 8.  Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.

Authors:  Fahad S M Alshehri; Claire S Whyte; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.